Latest Diabetes mellitus type 2 Stories
LOS ANGELES, June 8, 2012 /PRNewswire/ -- You are struggling with obesity. You have tried to lose weight through diet and exercise, only to finally give up in frustration when they failed to deliver any tangible results. You know you're not alone with this problem, and yet you feel ashamed anyway. It's no surprise; society has not been kind to the obesity epidemic. There is a certain stigma attached to weight, and there is a certain stigma attached to bariatric surgery as well. Too...
BOSTON, June 6, 2012 /PRNewswire/ -- Rhythm announced today the initiation of a Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of gastroparesis in patients with Type I and Type II diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastric motility. "We are excited about the clinical profile of RM-131 as we bring it forward into Phase 2 development," said Liz Stoner, MD, Chief Development Officer of Rhythm....
RIDGEFIELD, Conn., and INDIANAPOLIS, June 5, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American Diabetes Association (ADA) Scientific Sessions® in Philadelphia, June...
RARITAN, N.J., June 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that data from five Phase 3 clinical studies evaluating the safety and efficacy of canagliflozin, an investigational sodium glucose co-transporter 2 (SLGT2) inhibitor, will be presented at the American Diabetes Association (ADA) 72nd Annual Scientific Sessions, being held June 8-12, in Philadelphia, PA. Canagliflozin is an investigational SGLT2 inhibitor for the treatment...
CHESTERFIELD, Mo., June 2, 2012 /PRNewswire/ -- Reliv International (RELV) has incorporated a breakthrough ingredient into its patented, clinically proven GlucAffect(®) formula. The addition of LunaRich comes less than a month after the CDC published findings from the National Health and Nutrition Examination Survey indicating metabolic syndrome continues to rise among Americans. Fighting an EpidemicMetabolic syndrome -- a cluster of symptoms including high blood sugar,...
A new study published online in the British Medical Journal (BMJ) has discovered a possible link between one popular type of diabetes drug and the risk of bladder cancer. According to Telegraph Medical Correspondent Stephen Adams, a team of Canadian researchers, led by Dr. Laurent Azoulay of the Jewish General Hospital in Montreal, studied U.K. National Health Service (NHS) statistics and learned that individuals with Type 2 diabetes who had taken pioglitazone (Actos) had an 83% higher...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 29, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 24, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.[1]...
BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis. The trial demonstrated that RM-131 greatly accelerates gastric emptying in patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2012 conference in San Diego. The Phase 1b clinical trial was a randomized, double-blind, placebo-controlled, single-dose...
New interdisciplinary conference brings together leading researchers and stakeholders to discuss the latest in obesity, cancer, diabetes and related metabolic disorders WASHINGTON, May 22, 2012 /PRNewswire-USNewswire/ -- Obesity is a national epidemic, affecting millions of Americans and increasing their risk for serious obesity-related illnesses,[i] including heart disease, stroke, type 2 diabetes and certain types of cancer.[i] In an effort to combat the problem, scientists and...
